Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (812)	12/11/2000 4:36:05 AM
From: nigel bates	Respond to of 1475

"Under the terms of the merger agreement, BioTransplant plans to issue 6.6 million shares of its common stock to the holders of shares of capital stock of Eligix. The transaction is subject to stockholder approval and customary closing conditions, and is expected to close in late Q1 2001.... Eligix, Inc. is a privately held biomedical company engaged in the development of cellular transplantation and immune therapies to enhance human immune response to cancers and infectious diseases, reduce the risk of infection and hypersensitivity reactions in blood transfusions and to achieve immune tolerance in organ transplant and autoimmune disorders. The Company's core technologies originated as a result of research at Coulter Corporation, in collaboration with physicians at Harvard University's Dana-Farber Cancer Institute, and Johns Hopkins University. Eligix' products under development are high-density microparticles (HDM) with monoclonal antibodies on their surfaces. These antibodies attach with high specificity to target blood or tumor cells. The particles, when mixed with donor or patient peripheral blood or bone marrow cells, circulate rapidly through the cell suspension and attach to their target cells. The particles settle by gravity with their targeted cells, effectively removing unwanted cells, or capturing desired cells for therapeutic purposes. Processing of blood or marrow with HDM can be performed in a simple, brief laboratory procedure with consistent results of 99.99% or greater depletion of target cells. Eligix is seeking to commence Phase III clinical trials in the U.S., and to obtain CE Mark approval in Europe, for its lead products, BCell-HDM and TCell-HDM. BCell-HDM is targeted for purging of malignant B cells from autologous stem cell transplants for lymphoma, myeloma and certain leukemias; TCell-HDM is targeted for depletion of graft versus host disease- causing cells from therapeutic donor leukocyte infusions....